Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries
Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries. NEW YORK (Reuters) - Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one way his administration would seek to lower drug costs to consumers could be through an international pricing index (IPI) that would determine what Medicare pays for certain medicines based on the prices set in a handful of other countries. Frazier, a lawyer by trade, did not say whether Merck would launch its own legal challenge to the proposed rule.